▁individual . ▁These ▁companion ▁di agnostics ▁have ▁incorpor ated ▁the ▁ph arm ac ogen omic ▁information ▁related ▁to ▁the ▁drug ▁into ▁their ▁pres cription ▁label ▁in ▁an ▁effort ▁to ▁assist ▁in ▁making ▁the ▁most ▁optimal ▁treatment ▁decision ▁possible ▁for ▁the ▁patient . ▁ ▁D rug ▁development ▁and ▁usage ▁ ▁Having ▁an ▁individual ' s ▁genom ic ▁information ▁can ▁be ▁significant ▁in ▁the ▁process ▁of ▁developing ▁dru gs ▁as ▁they ▁await ▁appro val ▁from ▁the ▁F DA ▁for ▁public ▁use . ▁Having ▁a ▁detailed ▁account ▁of ▁an ▁individual ' s ▁gen etic ▁make - up ▁can ▁be ▁a ▁major ▁asset ▁in ▁dec iding ▁if ▁a ▁patient ▁can ▁be ▁chosen ▁for ▁inclusion ▁or ▁ex clusion ▁in ▁the ▁final ▁stages ▁of ▁a ▁clin ical ▁trial . ▁Being ▁able ▁to ▁identify ▁patients ▁who ▁will ▁benefit ▁most ▁from ▁a ▁clin ical ▁trial ▁will ▁increase ▁the ▁safety ▁of ▁patients ▁from ▁ad verse ▁out comes ▁caused ▁by ▁the ▁product ▁in ▁testing , ▁and ▁will ▁allow ▁smaller ▁and ▁faster ▁tri als ▁that ▁lead ▁to ▁lower ▁overall ▁costs . ▁In ▁addition , ▁dru gs ▁that ▁are ▁de emed ▁in effect ive ▁for ▁the ▁larger ▁population ▁can ▁gain ▁appro val ▁by ▁the ▁F DA ▁by ▁using ▁personal ▁genom es ▁to ▁qual ify ▁the ▁effect iveness ▁and ▁need ▁for ▁that ▁specific ▁drug ▁or ▁ther apy ▁even ▁though ▁it ▁may ▁only ▁be ▁needed ▁by ▁a ▁small ▁percentage ▁of ▁the ▁population ., ▁ ▁Today ▁in ▁medicine , ▁it ▁is ▁common ▁that ▁phys icians ▁often ▁use ▁a ▁trial ▁and ▁error ▁strategy ▁until ▁they ▁find ▁the ▁treatment ▁ther